Abstract 148P
Background
The purpose of this study was to compare Capecitabine and Oxaliplatin (XELOX) with S-1, based on disease-free survival (DFS) and overall survival (OS) in gastric cancer (GC). In addition, clinical impact of using lymph node ratios and compare it with N stage was investigated.
Methods
Patients who had curative resection and received either S-1 or XELOX as adjuvant chemotherapy for advanced gastric cancer between Jan, 2011 and Dec, 2015, were analysed. Of the 412 patients enrolled, 301 received S-1 and 111 received XELOX. Lymph node ratio (LNR) groups were segregated as 0, 0-0.1, 0.1-0.25, and > 0.25 and named LNR 0,1,2 and 3, respectively. Propensity score matching (PSM) was used to minimize the influence of potential selection bias. The PSM compared DFS and OS in the two treatment groups, and enabled subgroup analysis according to clinical variables including the lymph node ratio group (LNR group) and N stage.
Results
In PSM cohort, the sample size of each group was 86 patients and variables are well balanced. The XELOX group showed significantly better DFS (26.9% vs 59.3%, HR 0.43, 95% CI 0.20-0.90; p = 0.025) and better OS(30.8% vs 63.0%, HR 0.44, 95% CI 0.20-0.99; 0.045) in stage IIIC. The XELOX group showed significantly better DFS in all stage III. (54.7% vs 61.6%, HR 0.57 ,95% CI 0.33-0.99; p = 0.045). The N3 group showed significantly better DFS (40% vs 65.8%, HR 0.45, 95% CI, 0.23-0.86; p = 0.017) and better OS (44.7% vs 68.4%, HR 0.48, 95% CI, 0.24-0.97; p = 0.040) in the XELOX group. The LNR 3 group showed significantly better DFS in the XELOX group (26.3% vs 52.9% with HR 0.41 (95% CI, 0.17-0.97; p = 0.042).
Conclusions
Our data suggested that current N staging and LNR could be a useful tool for selecting patients who can benefit from adjuvant XELOX after D2 gastrectomy when compared with S-1. When patients who are designated N3 or LNR > 0.25 or at stage IIIC, XELOX should be recommended over S-1.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis
Presenter: Jinhai Gou
Session: Poster display session
Resources:
Abstract
250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities
Presenter: Gonçalo Nogueira da Costa
Session: Poster display session
Resources:
Abstract
251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years
Presenter: Xiu Ming
Session: Poster display session
Resources:
Abstract
252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome
Presenter: Ashraf Fadlelseid
Session: Poster display session
Resources:
Abstract
253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8+ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1
Presenter: Junsik Park
Session: Poster display session
Resources:
Abstract
254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
Presenter: Diar Aziz
Session: Poster display session
Resources:
Abstract
255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data
Presenter: Huining Jing
Session: Poster display session
Resources:
Abstract
256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
Presenter: E Yang
Session: Poster display session
Resources:
Abstract
257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India
Presenter: Rakesh M. P
Session: Poster display session
Resources:
Abstract
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract